TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6741447

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories after halothane anaesthesia
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg suppositories after enflurane anaesthesia
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories after enflurane anaesthesia
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg suppositories after halothane anaesthesia
Number of subjects: 91
Study: 29843528

Group type: EXPERIMENTAL
Intervention: Writing about potentially 'therapeutic' topics
Number of subjects: 68

Group type: COMPARATOR
Intervention: Writing about daily events
Number of subjects: 68
Study: 27852684

Group type: EXPERIMENTAL
Intervention: 150 mg/day resveratrol (resVida)
Number of subjects: 17
Study: 23617557

Group type: EXPERIMENTAL
Intervention: One-step method (2-h, 75 g oral glucose tolerance test)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Two-step method (50 g glucose challenge test followed by 100 g OGTT)
Number of subjects: 786

Group type: COMPARATOR
Intervention: GCT-negative group
Number of subjects: 786

Group type: COMPARATOR
Intervention: C&C-negative group
Number of subjects: 786
Study: 23588128

Group type: EXPERIMENTAL
Intervention: Self-administered paper-and-pencil questionnaire measuring perceived risk for STIs
Number of subjects: 1192
Study: 21174921

Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone
Number of subjects: 450

Group type: COMPARATOR
Intervention: No steroids (Control group)
Number of subjects: 450
Study: 19094438

Group type: EXPERIMENTAL
Intervention: 5 mg levobupivacaine 0.5% mixed with 25 microg fentanyl (group LF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 7.5 mg levobupivacaine 0.5% (group L)
Number of subjects: 40
Study: 16627843

Group type: EXPERIMENTAL
Intervention: Microphone announcement
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Telephone announcement
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Computer announcement
Number of subjects: 1000
Study: 14531504

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (seminars, outreach visits, reminders, CME small group training)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 727
Study: 10924301

Group type: EXPERIMENTAL
Intervention: Oral magnesium (10.3 mmol)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Sotalol and oral magnesium
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sotalol and placebo
Number of subjects: 301
Study: 8880817

Group type: EXPERIMENTAL
Intervention: Cisatracurium 80 micrograms.kg-1 during N2O-O2-halothane anaesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cisatracurium 100 micrograms.kg-1 during N2O-O2-opioid anaesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neostigmine 45 micrograms.kg-1 with glycopyrrolate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 32
Study: 1529944

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6827

Group type: COMPARATOR
Intervention: Prevention trial
Number of subjects: 6827

Group type: COMPARATOR
Intervention: Treatment trial
Number of subjects: 6827
Study: 3981321

Group type: EXPERIMENTAL
Intervention: Preterm milk with iron supplementation (2 mg/kg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mature human milk with iron supplementation (2 mg/kg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infant formula with iron supplementation (2 mg/kg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preterm milk without iron supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mature human milk without iron supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infant formula without iron supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preterm milk with routine multivitamin supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mature human milk with routine multivitamin supplementation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Infant formula with routine multivitamin supplementation
Number of subjects: 36
Study: 31960705

Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study: 29383426

Group type: EXPERIMENTAL
Intervention: 99mTc-Antimony colloid (Group-1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 99mTc-Sulphur colloid (Group-2)
Number of subjects: 78
Study: 26902092

Group type: EXPERIMENTAL
Intervention: 50 g of dried plum
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 g of dried plum
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 24525660

Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/d)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Escitalopram (10 mg/d)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both Tianeptine and Escitalopram
Number of subjects: 164
Study: 22463596

Group type: EXPERIMENTAL
Intervention: Good adherence (never missed pills in the last month)
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: 100% Drug Possession Ratio (DPR) throughout the first year
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Poor adherence (self-reported measures)
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Poor adherence subgroup by Markov Chain (MC)
Number of subjects: 2960

Group type: EXPERIMENTAL
Intervention: Poor adherence subgroup by Drug Possession Ratio (DPR)
Number of subjects: 2960
Study: 20674286

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19256286

Group type: EXPERIMENTAL
Intervention: No Smoking is a Norm programme
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1423
Study: 16167789

Group type: EXPERIMENTAL
Intervention: PGE1 (0.05 microg x kg(‐1) x min(‐1) administered intravenously during surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PGE1 administration)
Number of subjects: 30
Study: 12800126

Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy and bupropion
Number of subjects: 0
Study: 10992178

Group type: EXPERIMENTAL
Intervention: Postoperative administration of low-dose cyclic oral contraceptives for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study: 8833056

Group type: EXPERIMENTAL
Intervention: Combination treatment (MTX 5/50-7.5/100 mg/week/day)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA 50-150 mg/day)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX 5-15 mg/week)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Combination treatment and AZA
Number of subjects: 209
Study: 1459383

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises for stress incontinence and bladder training for urge incontinence
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no treatment for first 3 months)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises for stress incontinence and bladder training for urge incontinence (after initial control period)
Number of subjects: 110
Study: 6147300

Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: No beta-adrenoceptor blockade (Control)
Number of subjects: 0
Study: 29855682

Group type: EXPERIMENTAL
Intervention: Traditional core decompression (CD)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: CD combining bone grafting (BG)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: CD combining bone marrow mononuclear cells (BMMC)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: CD combining BG and BMMC
Number of subjects: 453

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 453
Study: 28714081

Group type: EXPERIMENTAL
Intervention: High positive schizotypes after sleep deprivation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 36
Study: 26184697

Group type: EXPERIMENTAL
Intervention: Group native airway, nonintubated, propofol (NA)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group intubated, sevoflurane (IS)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group intubated, propofol (IP)
Number of subjects: 179
Study: 23175563

Group type: EXPERIMENTAL
Intervention: DHP + primaquine (0.75 mg/kg single dose on day 3)
Number of subjects: 349

Group type: COMPARATOR
Intervention: DHP only
Number of subjects: 349
Study: 21244169

Group type: EXPERIMENTAL
Intervention: Caffeine consumption (amount not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing in the afternoon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testing in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diurnal variation
Number of subjects: 0
Study: 18433844

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day for 5 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day for 5 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16769523

Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP) model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EBP model
Number of subjects: 0
Study: 14677161

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) + stretching exercises
Number of subjects: 62

Group type: COMPARATOR
Intervention: Stretching exercises alone
Number of subjects: 62
Study: 11100000

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 8775351

Group type: EXPERIMENTAL
Intervention: Dynamic exercise (treadmill)
Number of subjects: 10
Study: 1727902

Group type: EXPERIMENTAL
Intervention: Intravenous 2',3'-dideoxyinosine (ddI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral 2',3'-dideoxyinosine (ddI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Plasma ddI concentration
Number of subjects: 48
Study: 6724661

Group type: EXPERIMENTAL
Intervention: High protein supplement (58 g/day of a 60:40 mixture of soy and wheat proteins)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low protein supplement (7 g/day of rice protein)
Number of subjects: 18
Study: 30099542

Group type: EXPERIMENTAL
Intervention: Stair-use prompts (signs)
Number of subjects: 13544

Group type: COMPARATOR
Intervention: No signs (control)
Number of subjects: 13544
Study: 29389170

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 26551600

Group type: EXPERIMENTAL
Intervention: Mother-infant psychoanalytic treatment (MIP) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Child Health Center care (CHCC) group
Number of subjects: 80
Study: 24307655

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Sulfinpyrazone
Number of subjects: 1000000
Study: 22445769

Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS+) reinforced by electrical stimulation (US)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulus (CS-) that was never reinforced
Number of subjects: 0
Study: 19720342

Group type: EXPERIMENTAL
Intervention: Herbal drug (500 mg of saffron, celery seed, and anise extracts three times a day for three days)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 17596273

Group type: EXPERIMENTAL
Intervention: Nebulisation of rhDNase before bedtime
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nebulisation of rhDNase after waking up
Number of subjects: 24
Study: 15213023

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 12577351

Group type: EXPERIMENTAL
Intervention: 84.5% ginsenoside retention enema for 4‐6 hrs every day, 6‐8 days consecutively before surgical operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline retention enema for 4‐6 hrs every day, 6‐8 days consecutively before surgical operation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 84.5% ginsenoside retention enema
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline retention enema
Number of subjects: 50
Study: 9530843

Group type: EXPERIMENTAL
Intervention: High-load conditions with attention-demanding tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-load conditions with attention-demanding tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-load manipulation of a visuospatial task requiring performance monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuospatial task with little monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression with different loads
Number of subjects: 0
Study: 8788323

Group type: EXPERIMENTAL
Intervention: SBT plus structured meal plans and grocery lists
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: SBT plus meal plans plus food provision (shared cost)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: SBT plus meal plans plus free food provision
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard behavioral treatment program (SBT)
Number of subjects: 163
Study: 2076403

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study: 7350310

Group type: EXPERIMENTAL
Intervention: Sucrose electrolyte oral solution
Number of subjects: 111

Group type: COMPARATOR
Intervention: Glucose electrolyte oral solution
Number of subjects: 111
Study: 30755381

Group type: EXPERIMENTAL
Intervention: IA‐TXA (15 mg/kg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: IV‐TXA (10 mg/kg)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: IA‐TXA (15 mg/kg) and IV‐TXA (10 mg/kg)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No‐TXA
Number of subjects: 228
Study: 27002859

Group type: EXPERIMENTAL
Intervention: Workplace intervention comprising four campaigns focused on gender and violence against women, alcoholism, sexual and reproductive health, and HIV/AIDS; implemented over 10 months with various interactive methods.
Number of subjects: 835

Group type: COMPARATOR
Intervention: Delayed control group (no specific intervention details provided).
Number of subjects: 835
Study: 23582675

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of darbepoetin-alpha (DA) 150 μg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 56
Study: 21830967

Group type: EXPERIMENTAL
Intervention: linaclotide 145 μg
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: linaclotide 290 μg
Number of subjects: 1276

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: linaclotide (both doses)
Number of subjects: 1276
Study: 19207722

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine tablet
Number of subjects: 15
Study: 17115870

Group type: EXPERIMENTAL
Intervention: 3 sessions of rapid smoking plus counseling
Number of subjects: 67

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 67
Study: 15178988

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New stents and delivery systems
Number of subjects: 0
Study: 11370797

Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/day) for 12 weeks
Number of subjects: 82
Study: 9198730

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF) 15 mg bid
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 8458924

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate 6 mg per os daily + intravaginal micronized progesterone 600 mg daily
Number of subjects: 378

Group type: COMPARATOR
Intervention: Intravaginal micronized progesterone 600 mg daily
Number of subjects: 378
Study: 3007984

Group type: EXPERIMENTAL
Intervention: Intravenous cytomegalovirus immune globulin and seronegative blood products
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Seronegative blood products alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Globulin alone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Seronegative blood products
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard blood products
Number of subjects: 97
Study: 30590410

Group type: EXPERIMENTAL
Intervention: mAHTPred (meta-predictor using ensemble learning of four ML algorithms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline predictors (ERT-based models)
Number of subjects: 0
Study: 29900829

Group type: EXPERIMENTAL
Intervention: Alternative TNFi
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 149

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 149
Study: 26420772

Group type: EXPERIMENTAL
Intervention: WIN (group A)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Incognito (group B)
Number of subjects: 630
Study: 24784763

Group type: EXPERIMENTAL
Intervention: TDF (Tenofovir disoproxil fumarate)
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: FTC/TDF (Tenofovir disoproxil fumarate with Emtricitabine)
Number of subjects: 4747

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: Cases (HIV seroconverters)
Number of subjects: 4747
Study: 22675968

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppositories (100 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Indomethacin suppositories (100 mg/day)
Number of subjects: 70
Study: 20099281

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in Alu
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in Alu among those aged 70 or older
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among individuals with a family history of cancer
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among current alcohol drinkers
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among current smokers
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among those who rarely or never consumed fruit
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among CC carriers for the MTRR Ex5+123C>T polymorphism
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among TT carriers for the MTRR Ex15+572T>C polymorphism
Number of subjects: 723
Study: 17509235

Group type: EXPERIMENTAL
Intervention: Dapsone (200 mg single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15691257

Group type: EXPERIMENTAL
Intervention: Atypical nevi (AN)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Clearly benign nevi (BN)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Melanoma (MM)
Number of subjects: 459
Study: 12060479

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy of tazarotene and mometasone furoate
Number of subjects: 20

Group type: COMPARATOR
Intervention: All topical therapy regimens
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with skin type 1 and 2
Number of subjects: 20
Study: 9919319

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8789310

Group type: EXPERIMENTAL
Intervention: Quadruple therapy with omeprazole, bismuth, tetracycline and metronidazole for 1 week (pretreated with omeprazole for 3 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Dual therapy with omeprazole and amoxicillin for 2 weeks
Number of subjects: 76
Study: 1872398

Group type: EXPERIMENTAL
Intervention: Graded balloon distensions (1 min duration at 10-min intervals in 8-ml stepwise increments)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unperceived orad distensions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 20-cm-caudad distensions at higher levels
Number of subjects: 11
Study: 7175837

Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring
Number of subjects: 690

Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 690

Group type: COMPARATOR
Intervention: Electronic fetal monitoring with scalp pH sample option
Number of subjects: 690

Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Prolonged hours of internal catheter usage greater than 8 hours
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membranes greater than 12 hours
Number of subjects: 690
Study: 30322847

Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (CPB) at 35°C‐36°C
Number of subjects: 200
Study: 27396580

Group type: EXPERIMENTAL
Intervention: Elastic band-based high-speed power training (HSPT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-speed strength training (LSST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30